SI
SI
discoversearch

Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
103 46 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
103Poster gives me more clarity on cytokine response than the abstract that only gasemi_infinite -last Sunday
102I posted some TRIL SITC observations starting here: twitter.comBiomaven-last Sunday
101Found some background data on cytokines for comparison with Tril data released isemi_infinite -November 8
100To my uneducated eye, the abstracts for ASH look pretty interesting, especially Bladerunner17-November 7
99Peter had commented in valuation thread that "If you take a stock like Trisemi_infinite -November 7
98TRIL hits another 52-week high at $10.10. $10 may hold today. BladerunnerBladerunner17-November 7
97TRIL hits new 52-week high. ($10) It has pulled back some. BladerunnerBladerunner17-November 6
96<At the same time, there is no need for the company to rush business developmMiljenko Zuanic-November 6
95The bull case for TRIL from "Seeking Alpha" The CD47 Space Is HeatinBladerunner17-November 5
94ASH abstracts now available, and TRIL has 2. 1/6 OR in DLBCL for monotherapy, btuck-November 1
93Good size round B, Forty Seven Inc...... markets.businessinsider.com (pointer scaram(o)uche-October 17
92TRIL analysis from "Seeking Alpha" seekingalpha.com Summary SharesBladerunner17-October 15
91Competition . . . "tril-investor" handicaps the players ituck-October 6
90Getting ready for clear above 5.35. [graphic]hollyhunter-October 3
89Here is the link its 1:30pm (Eastern) wsw.com BTW for those that don't knowghmm1September 28
88Tuck, I talked to Jim Parsons today. TRIL will have a poster at ASH. On TRIL&Bladerunner17-September 27
87>>>> asked by the company to change its business description in the tuck1August 31
86So, TRIL will continue to develop the EGFR inhibitor, while putting up the BET ituck-August 31
85I wonder about the CD200 program. There doesn't seem to be the same level oftuck-August 4
84So, TRIL will continue to develop the EGFR inhibitor, while putting up the BET ituck-July 5
83That occurred to me, and may be a part of it. So far, the in vivo experiments htuck-June 26
82 >>>Then inexplicably off 10% today to new lows. Could be end-of-quartBulbaMan-June 26
81PD-1 combo now being studied. With Nivolumab, as an expansion of the ongoing P1tuck-June 26
80Updating the Novimmune bispecific effort. In addition to the CD47/CD19 bispeciftuck-April 4
79Can't find the post, but somewhere around here I said that it was possible tscaram(o)uche-March 31
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.